Advertisement
Advertisement
U.S. markets open in 7 hours 5 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Immutep Limited (IMMP)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.1400-0.1000 (-4.46%)
At close: 04:00PM EDT
Advertisement

Immutep Limited

Australia Square
Level 33 264 George Street
Sydney, NSW 2000
Australia

https://www.immutep.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Marc VoigtCEO, MD, CFO, Chief Bus. Officer & Exec. Director390.77kN/A1973
Ms. Deanne Miller LLBCOO, Gen. Counsel & Joint Company Sec.256.55kN/A1977
Dr. Frederic Triebel M.D., Ph.D.Chief Scientific Officer & Chief Medical Officer388.46kN/A1955
Ms. Indira NaiduJoint Company Sec.N/AN/AN/A
Mr. Christian MuellerDirector of Clinical Devel. & Regulatory AffairsN/AN/AN/A
Mr. Shengfei FangFin. Director & Assistant Company Sec.N/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.

Corporate Governance

Immutep Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement